Aug 08, 2022 / 03:00PM GMT
Operator
Welcome to the Salarius Pharmaceuticals second-quarter 2022 financial results and business update conference call. All participants will be in listen-only mode. (Operator Instructions) After today's presentation, there will be an opportunity to ask questions. (Operator Instructions) Please note this event is being recorded.
I would now like to turn the conference over to Kim Golodetz with LHA Investor Relations. Kim, please go ahead.
Kim Golodetz - LHA Investor Relations - Senior VP & Principal
Thank you. This is Kim Golodetz, Senior Vice President and Principal with LHA Investor Relations. Thank you all for participating in today's call.
Joining me from Salarius Pharmaceuticals are David Arthur, Director and Chief Executive Officer; and Mark Rosenblum, Chief Financial Officer. In addition, Dr. Daniela Santiesteban, Director of Protein Degradation Development, will be available for Q&A.
During this call, Salarius will be making forward-looking statements about operating metrics, future expectations, plans, events, and
Q2 2022 Salarius Pharmaceuticals Inc Earnings Call Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot